Publikationen
2023
Dimopoulos MA, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trněný M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Chan WY, Schneider J, Allewelt H, Patel S, Cohen A, Tam CS.J Clin Oncol. 2023 Jul 21:JCO2202830. doi: 10.1200/JCO.22.02830. Online ahead of print.PMID: 37478390
Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Phillips EH, Dreyling M, Seymour JF, Grigg A, Trotman J, Lin TY, Hong XN, Kingbiel D, Nielsen TG, Knapp A, Herold M, Marcus R.Hemasphere. 2023 Jun 30;7(7):e919. doi: 10.1097/HS9.0000000000000919. eCollection 2023 Jul.PMID: 37404773
Buske C, Dimopoulos MA, Morel P; European Consortium for Waldenström's Macroglobulinemia (ECWM).J Clin Oncol. 2023 Jun 22:JCO2300877. doi: 10.1200/JCO.23.00877. Online ahead of print.PMID: 37348018
Defrancesco I, Ferretti VV, Morel P, Kyriakou C, Kastritis E, Tohidi-Esfahani I, Tedeschi A, Buske C, García-Sanz R, Vos JMI, Peri V, Margiotta Casaluci G, Ferrari A, Piazza F, Oostvogels R, Lovato E, Montes L, Fornecker LM, Grunenberg A, Dimopoulos MA, Tam CS, D'Sa S, Leblond V, Trotman J, Passamonti F, Arcaini L, Varettoni M.Hemasphere. 2023 Jun 2;7(6):e887. doi: 10.1097/HS9.0000000000000887. eCollection 2023 Jun.PMID: 37283569
Future Directions in the Frontline Management of Waldenström Macroglobulinemia.
Buske C, Palomba ML.Hematol Oncol Clin North Am. 2023 Aug;37(4):719-725. doi: 10.1016/j.hoc.2023.05.001. Epub 2023 Jun 1.PMID: 37270384
D'Sa S, Matous JV, Advani R, Buske C, Castillo JJ, Gatt M, Kapoor P, Kersten MJ, Leblond V, Leiba M, Palomba ML, Paludo J, Qiu L, Sarosiek S, Shadman M, Talaulikar D, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Trotman J, Varettoni M, Vos J, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Kastritis E.Semin Hematol. 2023 Mar;60(2):80-89. doi: 10.1053/j.seminhematol.2023.03.003. Epub 2023 Mar 27.PMID: 37147252
A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML.
Bamezai S, Pulikkottil AJ, Yadav T, Vegi NM, Mueller J, Mark J, Mandal T, Feder K, Ihme S, Song C, Rosler R, Wiese S, Hoell JI, Kloetgen A, Karsan A, Kumari A, Wojenski L, Sinha AU, Gonzalez-Menendez I, Quintanilla-Martinez L, Donato E, Trumpp A, Kruse E, Hamperl S, Zou L, Rawat VPS, Buske C.Blood. 2023 Jul 6;142(1):90-105. doi: 10.1182/blood.2022018651.PMID: 37146239
Tam CS, Kapoor P, Castillo JJ, Buske C, Ansell SM, Branagan AR, Kimby E, Li Y, Palomba ML, Qiu L, Shadman M, Abeykoon JP, Sarosiek S, Vos J, Yi S, Stephens D, Roos-Weil D, Roccaro AM, Morel P, Munshi NC, Anderson KC, San-Miguel J, Garcia-Sanz R, Dimopoulos MA, Treon SP, Kersten MJ.Semin Hematol. 2023 Mar;60(2):118-124. doi: 10.1053/j.seminhematol.2023.03.006. Epub 2023 Mar 24.PMID: 37099031
Stevens WBC, Los-de Vries GT, Langois-Jacques C, Clear AJ, Stathi P, Sander B, Rosenwald A, Calaminici M, Hoster E, Hiddemann W, Gaulard P, Salles G, Klapper W, Xerri L, Burton C, Tooze RM, Smith AG, Buske C, Scott DW, Natkunam Y, Advani R, Sehn LH, Raemaekers J, Gribben J, Lockmer S, Kimby E, Kersten MJ, Maucort-Boulch D, Ylstra B, van Dijk E, de Jong D.Hemasphere. 2023 Apr 5;7(4):e863. doi: 10.1097/HS9.0000000000000863. eCollection 2023 Apr.PMID: 37038467
Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA.Future Oncol. 2023 Feb;19(5):345-353. doi: 10.2217/fon-2022-1015. Epub 2023 Feb 23.PMID: 36815271
Buske C, Dimopoulos MA, Grunenberg A, Kastritis E, Tomowiak C, Mahé B, Troussard X, Hajek R, Viardot A, Tournilhac O, Aurran T, Lepretre S, Zerazhi H, Hivert B, Leblond V, de Guibert S, Brandefors L, Garcia-Sanz R, Gomes da Silva M, Kimby E, Schmelzle B, Kaszynski D, Dreyhaupt J, Muche R, Morel P.J Clin Oncol. 2023 May 10;41(14):2607-2616. doi: 10.1200/JCO.22.01805. Epub 2023 Feb 10.PMID: 36763945
Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.Ann Oncol. 2023 Mar;34(3):325. doi: 10.1016/j.annonc.2022.11.009. Epub 2022 Dec 16.PMID: 36529567
Dogliotti I, Jiménez C, Varettoni M, Talaulikar D, Bagratuni T, Ferrante M, Pérez J, Drandi D, Puig N, Gilestro M, García-Álvarez M, Owen R, Jurczak W, Tedeschi A, Leblond V, Kastritis E, Kersten MJ, D'Sa S, Kaščák M, Willenbacher W, Roccaro AM, Poulain S, Morel P, Kyriakou C, Fend F, Vos JMI, Dimopoulos MA, Buske C, Ferrero S, García-Sanz R.Leukemia. 2023 Feb;37(2):388-395. doi: 10.1038/s41375-022-01762-3. Epub 2022 Nov 26.PMID: 36435884
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Castillo JJ, Buske C, Trotman J, Sarosiek S, Treon SP.Am J Hematol. 2023 Feb;98(2):338-347. doi: 10.1002/ajh.26788. Epub 2023 Jan 1.PMID: 36415104
Managing Waldenström's macroglobulinemia with BTK inhibitors.
Buske C, Jurczak W, Salem JE, Dimopoulos MA.Leukemia. 2023 Jan;37(1):35-46. doi: 10.1038/s41375-022-01732-9. Epub 2022 Nov 19.PMID: 36402930
2022
Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma.
Buske C. Lancet Oncol. 2022 Aug;23(8):967-969. doi: 10.1016/S1470-2045(22)00385-0. Epub 2022 Jul 5. PMID: 35803285
Dogliotti I, Jiménez C, Varettoni M, Talaulikar D, Bagratuni T, Ferrante M, Pérez J, Drandi D, Puig N, Gilestro M, García-Álvarez M, Owen R, Jurczak W, Tedeschi A, Leblond V, Kastritis E, Kersten MJ, D'Sa S, Kaščák M, Willenbacher W, Roccaro AM, Poulain S, Morel P, Kyriakou C, Fend F, Vos JMI, Dimopoulos MA, Buske C, Ferrero S, García-Sanz R. Leukemia. 2023 Feb;37(2):388-395. doi: 10.1038/s41375-022-01762-3. Epub 2022 Nov 26. PMID: 36435884
The EHA Research Roadmap: Malignant Lymphoid Diseases.
Dreyling M, André M, Gökbuget N, Tilly H, Jerkeman M, Gribben J, Ferreri A, Morel P, Stilgenbauer S, Fox C, Maria Ribera J, Zweegman S, Aurer I, Bödör C, Burkhardt B, Buske C, Dollores Caballero M, Campo E, Chapuy B, Davies A, de Leval L, Doorduijn J, Federico M, Gaulard P, Gay F, Ghia P, Grønbæk K, Goldschmidt H, Kersten MJ, Kiesewetter B, Landman-Parker J, Le Gouill S, Lenz G, Leppä S, Lopez-Guillermo A, Macintyre E, Mantega MVM, Moreau P, Moreno C, Nadel B, Okosun J, Owen R, Pospisilova S, Pott C, Robak T, Spina M, Stamatopoulos K, Stary J, Tarte K, Tedeschi A, Thieblemont C, Trappe RU, Trümper LH, Salles G. Hemasphere. 2022 May 19;6(6):e726. doi: 10.1097/HS9.0000000000000726. eCollection 2022 Jun. PMID: 35620592
Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV.
Los-de Vries GT, Stevens WBC, van Dijk E, Langois-Jacques C, Clear AJ, Stathi P, Roemer MGM, Mendeville M, Hijmering NJ, Sander B, Rosenwald A, Calaminici M, Hoster E, Hiddemann W, Gaulard P, Salles G, Horn H, Klapper W, Xerri L, Burton C, Tooze RM, Smith AG, Buske C, Scott DW, Natkunam Y, Advani R, Sehn LH, Raemaekers J, Gribben J, Kimby E, Kersten MJ, Maucort-Boulch D, Ylstra B, de Jong D. Blood Adv. 2022 Sep 27;6(18):5482-5493. doi: 10.1182/bloodadvances.2022008355. PMID: 35816682
Panayiotidis P, Tumyan G, Thieblemont C, Ptushkin VV, Marin-Niebla A, García-Sanz R, Le Gouill S, Stathis A, Bottos A, Hamidi H, Katz P, Perretti T, Willis JC, Buske C. Leuk Lymphoma. 2022 May;63(5):1058-1069. doi: 10.1080/10428194.2021.2015765. Epub 2022 Jan 19. PMID: 35045765
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle DL, Hess D, Moccia AA, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. Blood Adv. 2022 Jul 12;6(13):3911-3920. doi: 10.1182/bloodadvances.2021006520. PMID: 35537101
2021
Kwak LW, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Menne T, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Ogura M, Kim WS, Lee SJ, Kim SH, Ahn KY, Buske C.Clin Lymphoma Myeloma Leuk. 2021 Aug 28:S2152-2650(21)00362-1.
Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA.J Clin Oncol. 2021 Oct 4:JCO2100838. doi: 10.1200/JCO.21.00838. Online ahead of print.
Buske C, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Kwak L, Kim WS, Lee S, Kim S, Ahn K, Ogura M.Blood Adv. 2021 Sep 14;5(17):3354-3361. doi: 10.1182/bloodadvances.2021004484.PMID: 34477816
Pulikkottil AJ, Bamezai S, Ammer T, Mohr F, Feder K, Vegi NM, Mandal T, Kohlhofer U, Quintanilla-Martinez L, Sinha A, Buske C, Rawat VPS.Leukemia. 2021 Aug 30. doi: 10.1038/s41375-021-01390-3. Online ahead of print.PMID: 34462525
Trotman J, Buske C, Tedeschi A, Matous JV, MacDonald D, Tam CS, Tournilhac O, Ma S, Treon SP, Oriol A, Ping J, Briso EM, Arango-Hisijara I, Dimopoulos MA. Clin Cancer Res. 2021 Aug 11:clincanres.1497.2021. doi: 10.1158/1078-0432.CCR-21-1497. Online ahead of print. PMID: 34380643
Grunenberg A, Kaiser LM, Woelfle S, Schmelzle B, Viardot A, Möller P, Barth TFE, Muche R, Dreyhaupt J, Raderer M, Kiesewetter B, Buske C. BMC Cancer. 2021 Jun 29;21(1):749. doi: 10.1186/s12885-021-08464-6. PMID: 34187401
Kaiser LM, Harms M, Sauter D, Rawat VPS, Glitscher M, Hildt E, Tews D, Hunter Z, Münch J, Buske C. Cancers (Basel). 2021 Feb 16;13(4):826. doi: 10.3390/cancers13040826. PMID: 33669329
Dreyling M, Aurer I, Federico M, Jerkeman M, Kersten MJ, Linton K, Mey U, Tilly H, Buske C. Hemasphere. 2021 Jan 27;5(2):e529. doi: 10.1097/HS9.0000000000000529. eCollection 2021 Feb. PMID: 33880434
SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype.
Bongiovanni D, Klug M, Lazareva O, Weidlich S, Biasi M, Ursu S, Warth S, Buske C, Lukas M, Spinner CD, Scheidt MV, Condorelli G, Baumbach J, Laugwitz KL, List M, Bernlochner I. Cell Death Dis. 2021 Jan 5;12(1):50. doi: 10.1038/s41419-020-03333-9. PMID: 33414384
Bamezai S, Demir D, Pulikkottil AJ, Ciccarone F, Fischbein E, Sinha A, Borga C, Te Kronnie G, Meyer LH, Mohr F, Götze M, Caiafa P, Debatin KM, Döhner K, Döhner H, González-Menéndez I, Quintanilla-Fend L, Herold T, Jeremias I, Feuring-Buske M, Buske C, Rawat VPS. Leukemia. 2021 Feb;35(2):389-403. doi: 10.1038/s41375-020-0864-3. Epub 2020 May 15. PMID: 32409690
CXCR4 in Waldenström's Macroglobulinema: chances and challenges. Kaiser LM, Hunter ZR, Treon SP, Buske C. Leukemia. 2021 Feb;35(2):333-345. doi: 10.1038/s41375-020-01102-3. Epub 2020 Dec 3. PMID: 33273682
2020
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements.
Woolmore A, Arnold D, Blay JY, Buske C, Carrato A, Gerritsen W, Peeters M, Garcia-Foncillas J, Kerr D. Oncologist. 2020 Oct;25(10):e1428-e1432. doi: 10.1634/theoncologist.2019-0855. Epub 2020 May 21. PMID: 32333623
Dimopoulos M, Sanz RG, Lee HP, Trneny M, Varettoni M, Opat S, D'Sa S, Owen RG, Cull G, Mulligan S, Czyz J, Castillo JJ, Motta M, Siddiqi T, Gironella Mesa M, Granell Gorrochategui M, Talaulikar D, Zinzani PL, Askari E, Grosicki S, Oriol A, Rule S, Kloczko J, Tedeschi A, Buske C, Leblond V, Trotman J, Chan WY, Michel J, Schneider J, Tan Z, Cohen A, Huang J, Tam CS. Blood Adv. 2020 Dec 8;4(23):6009-6018. doi: 10.1182/bloodadvances.2020003010. PMID: 33284944
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M. Blood. 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844. PMID: 32731259
Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Talaulikar D, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastritis E. Lancet Haematol. 2020 Nov;7(11):e827-e837. doi: 10.1016/S2352-3026(20)30224-6. PMID: 33091356
Buske C. Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia. Lancet Haematol. 2020 Feb;7(2):e85-e86. doi: 10.1016/S2352-3026(19)30214-5. Epub 2019 Dec 19. PMID: 31866282.
Woolmore A, Arnold D, Blay JY, Buske C, Carrato A, Gerritsen W, Peeters M,Garcia-Foncillas J, Kerr D. The Oncology Data Network (ODN): Methodology, hallenges, and Achievements. Oncologist. 2020 Apr 25. doi:10.1634/theoncologist.2019-0855. Epub ahead of print. PMID: 32333623.
Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J,Wierzbowska A, Buske C; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Mar 17:S0923-7534(20)36079-8. doi: 10.1016/j.annonc.2020.02.018. Epub ahead of print. PMID: 2171751.
Woolmore A, Arnold D, Blay JY, Buske C, Carrato A, Gerritsen W, Peeters M, Garcia-Foncillas J, Kerr D. The Oncology Data Network (ODN): Methodology, Challenges, and Achievements. Oncologist. 2020 Apr 25. doi: 10.1634/theoncologist.2019-0855. Epub ahead of print. PMID: 32333623.
Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, Wierzbowska A, Buske C; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Mar 17:S0923-7534(20)36079-8. doi: 10.1016/j.annonc.2020.02.018. Epub ahead of print. PMID: 32171751.
Bamezai S, Demir D, Pulikkottil AJ, Ciccarone F, Fischbein E, Sinha A, Borga C, Te Kronnie G, Meyer LH, Mohr F, Götze M, Caiafa P, Debatin KM, Döhner K, Döhner H, González-Menéndez I, Quintanilla-Fend L, Herold T, Jeremias I, Feuring-Buske M, Buske C, Rawat VPS. TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. Leukemia. 2020 May 15. doi: 10.1038/s41375-020-0864-3. Epub ahead of print. PMID: 32409690.
Kerr D, Arnold D, Blay JY, Buske C, Carrato A, Gerritsen W, Peeters M. The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care. Oncologist. 2020 Jan;25(1):e1-e4. doi: 10.1634/theoncologist.2019-0337. Epub 2019 Sep 5. PMID: 31488619; PMCID: PMC6964115.
Vegi NM, Chakrabortty S, Zegota MM, Kuan SL, Stumper A, Rawat VPS, Sieste S, Buske C, Rau S, Weil T, Feuring-Buske M. Somatostatin receptor mediated targeting of acute myeloid leukemia by photodynamic metal complexes for light induced apoptosis. Sci Rep. 2020 Jan 15;10(1):371. doi: 10.1038/s41598-019-57172-6. PMID: 31941913; PMCID: PMC6962389.
Mayer S, Schmidtke-Schrezenmeier G, Buske C, Rücker FG, Barth TFE, Möller P, Marienfeld R. Rescue of Non-Informative Circulating Tumor DNA to Monitor the Mutational Landscape in NSCLC. Cancers (Basel). 2020 Jul 16;12(7):E1917. doi: 10.3390/cancers12071917. PMID: 32708545.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo J, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Chan WY, Schneider JY, Ro S, Cohen A, Huang J, Dimopoulos MA. A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY. Blood. 2020 Jul 30:blood.2020006844. doi: 10.1182/blood.2020006844. Epub ahead of print. PMID: 32731259.
2019
Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 Jan 24;133(4):299-305. doi: 10.1182/blood-2018-10-879593. Epub 2018 Dec 6. PMID: 30523119.
Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. doi: 10.1093/annonc/mdy146. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv270. Erratum in: Ann Oncol. 2019 May 1;30(5):860-862. Erratum in: Ann Oncol. 2019 May;30(5):860-862. Erratum in: Ann Oncol. 2018 Oct;29 Suppl 4:iv270. PMID: 29982402.
Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1530-1542. doi: 10.1016/S1470-2045(18)30618-1. Epub 2018 Oct 8. Erratum in: Lancet Oncol. 2019 Apr 29;: PMID: 30309758.
Altamura S, Vegi NM, Hoppe PS, Schroeder T, Aichler M, Walch A, Okreglicka K, Hültner L, Schneider M, Ladinig C, Kuklik-Roos C, Mysliwietz J, Janik D, Neff F, Rathkolb B, de Angelis MTH, Buske C, Silva ARD, Muedder K, Conrad M, Ganz T Kopf M, Muckenthaler MU, Bornkamm GW. Glutathione peroxidase 4 and vitamin E control reticulocyte maturation, stress erythropoiesis and iron homeostasis. Haematologica. 2020 Apr;105(4):937-950. doi: 10.3324/haematol.2018.212977. Epub 2019 Jun 27. PMID: 31248967; PMCID: PMC7109755.
Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M; ESMO Guidelines Committee. Electronic address: linicalguidelines@esmo.org. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jan;31(1):17-29. doi: 10.1016/j.annonc.2019.10.010. Epub 2019 Dec 4. PMID: 31912792.
Jurczak W, Długosz Danecka M, Buske C. Rituximab biosimilars for lymphoma in Europe. Expert Opin Biol Ther. 2019 Oct;19(10):1045-1056. doi: 10.1080/14712598.2019.1665017. PMID: 31512535.
Grunenberg A, Buske C. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia. Future Oncol. 2019 Aug;15(23):2687-2697. doi: 10.2217/fon-2019-0154. Epub 2019 Jun 11. PMID: 31184501.
Bamezai S, Buske C. Cutting Off Leukemogenesis: Hydra-like Plasticity of Mature Leukemic Cells. Cell Stem Cell. 2019 Aug 1;25(2):167-168. doi: 10.1016/j.stem.2019.07.005. PMID: 31374194.
Thoene S, Mandal T, Vegi NM, Quintanilla-Martinez L, Rösler R, Wiese S, Metzeler KH, Herold T, Haferlach T, Döhner K, Döhner H, Schwarzmüller L, Klingmüller U, Buske C, Rawat VPS, Feuring-Buske M. The ParaHox gene Cdx4 induces acute erythroid leukemia in mice. Blood Adv. 2019 Nov 26;3(22):3729-3739. doi: 10.1182/bloodadvances.2019000761. PMID: 31770439; PMCID: PMC6880902.
Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 May 1;30(5):860-862. doi: 10.1093/annonc/mdy466. Erratum for: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. PMID: 30520968.
Grunenberg A, Möller P, Viardot A, Teleanu V, Eiermann D, Buske C, Barth TF. Unusual transformation of primary extranodal marginal zone B cell lymphoma of the uterus into a nodal follicular lymphoma grade IIIB. Ann Hematol. 2019 Mar;98(3):797-799. doi: 10.1007/s00277-019-03598-x. Epub 2019 Jan 26. PMID: 30683997.
Grunenberg A, Möller P, Viardot A, Teleanu V, Eiermann D, Buske C, Barth TF. Unusual transformation of primary extranodal marginal zone B cell lymphoma of the uterus into a nodal follicular lymphoma grade IIIB. Ann Hematol. 2019 Mar;98(3):797-799. doi: 10.1007/s00277-019-03598-x. Epub 2019 Jan 26. PMID: 30683997.
2018
Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Jul 5. doi: 10.1093/annonc/mdy146.
Grigoryan A, Guidi N, Senger K, Liehr T, Soller K, Marka G, Vollmer A, Markaki Y, Leonhardt H, Buske C, Lipka DB, Plass C, Zheng Y, Mulaw MA, Geiger H, Florian MC. LaminA/C regulates epigenetic and chromatin architecture changes upon aging of hematopoietic stem cells. Genome Biol. 2018 Nov 7;19(1):189. doi:10.1186/s13059-018-1557-3. PMID: 30404662; PMCID: PMC6223039.
Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H,Richter J, Buske C; ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv261. doi: 10.1093/annonc/mdy159. Erratum for: Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51. PMID: 30285223.
Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5.
Hutchings M, Ladetto M, Buske C, de Nully Brown P, Ferreri AJM, Pfreundschuh M, Schmitz N, Balari AS, van Imhoff G, Walewski J; ESMO Lymphoma Consensus Conference Panel Members. ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients. Ann Oncol. 2018 Jun 19. doi: 10.1093/annonc/mdy167.
Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, Cohen A, Huang J, Buske C. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. Future Oncol. 2018 Jun 5. doi: 10.2217/fon-2018-0163.
Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Lennard A, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Coiffier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematol. 2018 Nov;5(11):e543-e553. doi: 10.1016/S2352-3026(18)30157-1. PMID: 30389036.
Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.
Kuchenbauer F, Buske C. Revisiting thrombocytopenia in acute promyelocytic leukemia. Leukemia. 2018 Jun;32(6):1477-1478. doi: 10.1038/s41375-018-0105-1. Epub 2018 Mar 23.
Buske C. In Reply. Dtsch Arztebl Int. 2018 Mar 16;115(11):190. doi: 10.3238/arztebl.2018.0190b
Alig S, Jurinovic V, Pastore A, Bararia D, Häbe S, Hellmuth JC, Kridel R, Gascoyne R, Schmidt C, Zöllner A, Buske C, Dreyling M, Unterhalt M, Hiddemann W, Hoster E, Weigert O. Impact of age on genetics and treatment efficacy in follicular lymphoma. Haematologica. 2018 Mar 15. pii: haematol.2018.187773. doi: 10.3324/haematol.2018.187773.
Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Ann Oncol. 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056.
Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, Richter J, Buske C; ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv261. doi: 10.1093/annonc/mdy159. Erratum for: Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51. PMID: 30285223.
Mandal T, Beck M, Kirsten N, Lindén M, Buske C. Targeting murine leukemic stem cells by antibody functionalized mesoporous silica nanoparticles. Sci Rep. 2018 Jan 17;8(1):989. doi: 10.1038/s41598-017-18932-4.
Buske C, Dreyling M. [Malignant B-Cell Lymphoma: Advances in the Therapy of Follicular Lymphoma and Mantle-cell Lymphoma]. Dtsch Med Wochenschr. 2018 Jan;143(1):46-51. doi: 10.1055/s-0043-124004. Epub 2018 Jan 9. German.
Herzig JK, Bullinger L, Tasdogan A, Zimmermann P, Schlegel M, Teleanu V, Weber D, Rücker FG, Paschka P, Dolnik A, Schneider E, Kuchenbauer F, Heidel FH, Buske C, Döhner H, Döhner K, Gaidzik VI. Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair. Oncotarget. 2017 Sep 21;8(56):95038-95053. doi: 10.18632/oncotarget.21119. eCollection 2017 Nov 10.
Schneider E, Staffas A, Röhner L, Malmberg ED, Ashouri A, Krowiorz K, Pochert N, Miller C, Wei SY, Arabanian L, Buske C, Döhner H, Bullinger L, Fogelstrand L, Heuser M, Döhner K, Xiang P, Ruschmann J, Petriv OI, Heravi-Moussavi A, Hansen CL, Hirst M, Humphries RK, Rouhi A, Palmqvist L, Kuchenbauer F. Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia. Haematologica. 2018 Feb;103(2):246-255. doi: 10.3324/haematol.2017.177485. Epub 2017 Dec 7.
Buske C, Hutchings M, Ladetto M, Goede V, Mey U, Soubeyran P, Spina M, Stauder R, Trnený M, Wedding U, Fields P; ESMO Lymphoma Consensus Conference Panel Members . ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Ann Oncol. 2018 Mar 1;29(3):544-562. doi: 0.1093/annonc/mdx413.
Buske C. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 Oct;32(5):821-827. doi: 10.1016/j.hoc.2018.05.009. Epub 2018 Jul 25. PMID: 30190020.
Dimopoulos MA, Salman Z, Buske C. Ibrutinib and Rituximab in Waldenström's Macroglobulinemia. N Engl J Med. 2018 Nov 15;379(20):1975-1976. doi: 10.1056/NEJMc1809505. PMID: 30428288.
Renteria R, Buske TR, Morrisett RA. Long-term subregion-specific encoding of enhanced ethanol intake by D1DR medium spiny neurons of the nucleus accumbens. Addict Biol. 2018 Mar;23(2):689-698. doi: 10.1111/adb.12526. Epub 2017 Jun 28. PMID: 28656742; PMCID: PMC6264790.
Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E; ESMO Lymphoma Consensus Conference Panel Members. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Ann Oncol. 2018 Feb 1;29(2):525. doi: 10.1093/annonc/mdx061. Erratum for: Ann Oncol. 2016 Dec;27(12):2149-2160. PMID: 28368466.
Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv270. doi: 10.1093/annonc/mdy322. Erratum for: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. PMID: 30285219.
Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG. Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study. Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1. PMID: 30275528; PMCID: PMC6286323.
Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, Richter J, Buske C; ESMO Guidelines Committee. Corrections to "Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann Oncol. 2018 Oct;29 Suppl 4:iv261. doi: 10.1093/annonc/mdy159. Epub 2020 Jan 7. Erratum for: Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51. PMID: 32169232.
Langgartner D, Füchsl AM, Kaiser LM, Meier T, Foertsch S, Buske C, Reber SO, Mulaw MA. Biomarkers for classification and class prediction of stress in a murine model of chronic subordination stress. PLoS One. 2018 Sep 5;13(9):e0202471. doi: 10.1371/journal.pone.0202471. PMID: 30183738; PMCID: PMC6124755.
2017
Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, Richter J, Buske C; ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51.
Kim WS, Buske C, Ogura M, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Osmanov D, Kwak LW, Lee SJ, Lee SY, Bae YJ, Coiffier B. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 2017 Aug;4(8):e362-e373. doi: 10.1016/S2352-3026(17)30120-5. Epub 2017 Jul 14. PMID: 28712940
Beck M, Mandal T, Buske C, Lindén M. Serum Protein Adsorption Enhances Active Leukemia Stem Cell Targeting of Mesoporous Silica Nanoparticles. ACS Appl Mater Interfaces. 2017 Jun 7;9(22):18566-18574. doi: 10.1021/acsami.7b04742. Epub 2017 May 25. PMID: 28525262
Buske C, Ogura M, Kwon HC, Yoon SW. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements. Future Oncol. 2017 May;13(15s):5-16. doi: 10.2217/fon-2017-0153. PMID: 28482702
Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C, ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2017 Apr 27. doi: 10.1093/annonc/mdx096. [Epub ahead of print] No abstract available. PMID: 28453614
Chakrabortty S, Agrawalla BK, Stumper A, Vegi NM, Fischer S, Reichardt C, Kögler M, Dietzek B, Feuring-Buske M, BuskeC, Rau S, Weil T. Mitochondria Targeted Protein-Ruthenium Photosensitizer for Efficient Photodynamic Applications. J Am Chem Soc. 2017 Feb 15;139(6):2512-2519. doi: 10.1021/jacs.6b13399. Epub 2017 Feb 7. PMID: 28097863
2016
Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.https://www.ncbi.nlm.nih.gov/pubmed/27956157 Lancet Oncol. 2016 Dec 9. pii: S1470-2045(16)30632-5. doi: 10.1016/S1470-2045(16)30632-5.
Krowiorz K, Ruschmann J, Lai C, Ngom M, Maetzig T, Martins V, Scheffold A, Schneider E, Pochert N, Miller C, Palmqvist L, Staffas A, Mulaw M, Bohl SR, Buske C, Heuser M, Kraus J, O'Neill K, Hansen CL, Petriv OI, Kestler H, Döhner H, Bullinger L, Döhner K, Humphries RK, Rouhi A, Kuchenbauer F. MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia. Blood Cancer J. 2016 Dec 9;6(12):e508. doi: 10.1038/bcj.2016.110.
Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016 Dec 7. doi: 10.1038/nature20598.
Buske C. Ofatumumab: another way to target CD20 in Waldenström's macroglobulinaemia? Lancet Haematol. 2016 Nov 30. pii: S2352-3026(16)30163-6. doi: 10.1016/S2352-3026(16)30163-6.
Gentner E, Vegi NM, Mulaw MA, Mandal T, Bamezai S, Claus R, Tasdogan A, Quintanilla-Martinez L, Grunenberg A, Döhner K, Döhner H, Bullinger L, Haferlach T, Buske C, Rawat VP, Feuring-Buske M. VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in mice. Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13563.
Cusan M, Vegi NM, Mulaw MA, Bamezai S, Kaiser LM, Deshpande AJ, Greif PA, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries KR, Armstrong SA, Hiddemann W, Feuring-Buske M, Buske C. Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N-terminus. Blood. 2016 Nov 8. pii: blood-2016-04-706978.
Bogen A, Buske C, Hiddemann W, Bohlander SK, Christ O. Variable aldehyde dehydrogenase activity and effects on chemosensitivity of primitive human leukemic cells. Exp Hematol. 2016 Nov 5. pii: S0301-472X(16)30695-6. doi: 10.1016/j.exphem.2016.10.012.
Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E; ESMO Lymphoma Consensus Conference Panel Members.. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Ann Oncol. 2016 Oct 4. pii: mdw419.
Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee..appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies). Ann Oncol. 2016 Sep;27(suppl 5):v143-v144.
Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, Dimopoulos MA. Treatment recommendations for Waldenström macroglobulinemia from the Eighth International Workshop on WM. Blood 2016 Jul 18. pii: blood-2016-04-711234.
Vegi NM, Klappacher J, Oswald F, Mulaw MA, Mandoli A, Thiel VN, Bamezai S, Feder K, Martens JH, Rawat VP, Mandal T, Quintanilla-Martinez L, Spiekermann K, Hiddemann W, Döhner K, Döhner H, Stunnenberg HG, Feuring-Buske M, Buske C. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML. Cell Rep. 2016 Jul 12;16(2):498-507.
Daria D, Kirsten N, Muranyi A, Mulaw M, Ihme S, Kechter A, Hollnagel M, Bullinger L, Döhner K, Döhner H, Feuring-Buske M, Buske C. GPR56 contributes to the development of acute myeloid leukemia in mice. Leukemia 2016 Aug;30(8):1734-41.
Daria D, Kirsten N, Muranyi A, Mulaw M, Ihme S, Kechter A, Bullinger L, Döhner K, Döhner H, Feuring-Buske M, Buske C. GPR56 contributes to the development of acute myeloid leukemia in mice. Leukemia 2016; Apr 11. doi: 10.1038/leu.2016.76.
Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C; ESMO Guidelines Committee. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; Apr 7. pii: mdw025.
Grunenberg A, Buske C. New developments in Waldenström's macroglobulinemia. Dtsch Med Wochenschr 2016; Feb;141(3):170-2. doi: 10.1055/s-0041-107960.
Schmid F, Schmid M, Müssel C, Sträng JE, Buske C, Bullinger L, Kraus JM, Kestler HA. GiANT: gene set uncertainty in enrichment analysis. Bioinformatics 2016; Feb 1. pii: btw030.
Grunenberg A, Buske C. Waldenström's macroglobulinemia : Current developments in diagnostics and therapy. Internist(Berl) 2016; Mar;57(3):238-44. doi: 10.1007/s00108-015-0005-7.
Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica2016; Feb;101(2):115-208. doi: 10.3324/haematol.2015.136739.
2015
Schneider D, Dühren-von Minden M, Alkhatib A, Setz C, van Bergen CA, Benkißer-Petersen M, Wilhelm I, Villringer S, Krysov S, Packham G, Zirlik K, Römer W, Buske C, Stevenson FK, Veelken H, Jumaa H. Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma. Blood 2015; 125(21): 3287-3296.
Hess G, Keller U, Scholz CW, Witzens-Harig M, Atta J, Buske C, Kirschey S, Ruckes C, Medler C, van Oordt C, Klapper W, Theobald M, Dreyling M. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. Leukemia 2015; 29(8): 1695-1701.
Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-Hösle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski DT, Karsan A, Heuser M, Hogge D, Camargo FD, Engelhardt S, Döhner H, Buske C, Jongen-Lavrencic M, Naldini L, Humphries RK, Kuchenbauer F. MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Exp Hematol 2015; pii: S0301-472X(15)00511-1.
Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kröger N, Thiele J, Buske C; ESMO Guidelines Committee. Philadelphia chromoseome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; Suppl. 5: V85-V99.
Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C; ESMO Guidelines Committee. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; Suppl. 5: v100-v107.
Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C, ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; Suppl. 5: v78-v84.
Buske C, Seymour J. Immunochemotherapy in Waldenström macroglobulinemia - still the backbone of treatment. Leuk Lymphoma. 2015 Jun 9: 1-6.
Schneider V, Zhang L, Rojewski M, Fekete N, Schrezenmeier H, Erle A, Bullinger L, Hofmann s, Götz M, Döhner K, Ihme S, Döher H, Buske C, Feuring-Buske M, Greiner J. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. Int J Cancer 2015, Apr 24. doi: 10.1002/ijc.29583.
2014 - 2000
2014
Buske C. Towards a chemotherapy-free approach in indolent lymphoma. Lancet Oncol. 2014 Nov;15(12):1281-2.
Fenaux P, Haase D, Sanz GF, Santini V, Buske C; ESMO Guidelines Working Group. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii57-69.
Edmaier KE, Stahnke K, Vegi N, Mulaw M, Ihme S, Scheffold A, Rudolph KL, Buske C. Expression of the lymphoid enhancer factor 1 (Lef-1) is required for normal hematopoietic stem and progenitor cell function. Leukemia. 2014 Jan;28(1):227-30.
Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Sauerland MC, Heinecke A, Krug U, Berdel WE, Buechner T, Woermann B, Hiddemann W, Bohlander SK, Marcucci G, Spiekermann K, Bloomfield CD, Hoster E; Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia. J Clin Oncol. 2014 Apr 7.
CR Stadler, N Vegi, MA Mulaw, KE Edmaier, VPS Rawat, A Dolnik, L Bullinger, B Heilmeier, L Quintanilla-Fend, K Spiekermann, W Hiddemann, K Döhner, H Döhner, M Feuring-Buske, C Buske; The leukemogenicity of Hoxa9 depends on alternative splicing. Leukemia 2014 AMBER13-LEU-1614R
2013
Buske C, Leblond V, Dimopoulos M, Kimby E, Jäger U, Dreyling M; ESMO Guidelines Working Group, Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi155-vi159.
Fey MF, Buske C; ESMO Guidelines Working Group. Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi138-vi143.
Herold T, Mulaw MA, Jurinovic V, Seiler T, Metzeler KH, Dufour A, Schneider S, Kakadia PM, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Dreyling M, Bohlander SK. High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature. Leuk Lymphoma. 2013 Aug;54(8):1652-7.
Wu Y, Ihme S, Feuring-Buske M, Kuan SL, Eisele K, Lamla M, Wang Y, Buske C, Weil T. A Core-Shell Albumin Copolymer Nanotransporter for High Capacity Loading and Two-Step Release of Doxorubicin with Enhanced Anti-Leukemia Activity. Adv Healthc Mater. 2013 Jun;2(6):884-94.
Chen L, Deshpande A, Banka D, Bernt KM, Dias S, Buske C, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Abrogation of MLL-AF10 and CALM-AF10 mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2013 Apr;27(4):813-22.
Buske C. & Leblond V. How I manage to treat Waldenstrom’s macroglobulinemia. Leukemia. 2013 Apr;27(4):762-72.
Grasedieck S, Sorrentino A, Langer C, Buske C, Döhner H, Mertens D, Kuchenbauer F. Circulating microRNAs in hematological diseases: principles, challenges and perspectives. Blood 2013 Jun 20;121(25):4977-84.
Diffner E, Beck D, Gudgin E, Thoms J, Knezevic K, Pridans C, Foster S, Goode D, Khong Lim W, Boelen L, Metzeler K, Micklem G, Bohlander S, Buske C, Burnett A, Ottersbach K, Vassiliou G, Olivier J, Wong J, Gottgens B, Huntly B, Pimanda JE. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukaemia. Blood. 2013 Mar 21;121(12):2289-300.
2012
Langer C, Rücker FG, Buske C, Döhner H, Kuchenbauer F. Targeted therapies through microRNAs: pulp or fiction? Ther Adv Hematol. 2012 Apr;3(2):97-104.
Buske C, Herold M, Willenbacher W, Dreyling M. Follikuläres Lymphom. Onkopedia-DGHO, Mai 2012.
Bamezai S, Rawat VP, Buske C. The Piwi - piRNA Axis: Pivotal Beyond Transposon Silencing. Stem Cells. 2012, 12: 2603-2611.
Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Rosée P, Kirchner H, Kiewe P, Keller U, Buske C, Viardot A, Dreyling M. Ann Hematol. 2012, 11: 1765-1772.
Metzeler KH, Heilmeier B, Edmaier KE, Rawat VPS, Dufour A, Doehner K, Feuring-Buske M, Braess J, Spiekermann K, Buchener T, Sauerland MC, Doehner H, Hiddemann W, Bohlander SK, Schlenk RF, Bullinger L, Buske C. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood 2012; 120 (10): 2118 - 2126.
Mulaw MA, Krause AJ, Deshpande AJ, Krause LF, Rouhi A, La Starza R, Borkhardt A, Buske C, Mecucci C, Ludwig WD, Lottaz C, Bohlander SK. CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12. Leukemia. 2012 May; 26(5): 1012 - 1019.
Mantelzell- Lymphom. Dreyling M, Herold M, Drach J, Rummel M, Buske C. Onkopedia-DGHO, März 2012.
Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Kakadia PM, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Hiddemann W, Spiekermann K. The FLT3ITD level has a high prognostic impact in NPM1 mutated, but not NPM1 unmutated AML with a normal karyotype. Blood. 2012 119: 4383-4386.
Rawat VP, Humphries RK, Buske C. Beyond HOX: the role of ParaHOX genes in normal and malignannt hematpoiesis. Blood. 2012 120(3): 519-527.
Grasedieck S, Schöler N, Bommer M, Niess JH, Tumani H, Rouhi A, Bloehdorn J, Liebisch P, Mertens D, Döhner H, Buske C, Langer C, Kuchenbauer F. Impact of serum storage conditions on microRNA stability. Leukemia. 2012, 26 (11): 2414-2416.
Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM, Bohlander SK, Braess J, Heinecke A, Sauerland MC, Bergel WE, Buechner T, Woermann BJ, Feuring-Buske M, Buske C, Creutzig U, Thiede C, Zwaan MC, van den Heuvel-Eibrink MM, Reinhardt D, Hiddemann W, Spiekermann K. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal kariotype AML (NK-AML). Ann Hematol 2012; 91: 9-18.
Azimzadeh O, Scherthan H, Yentrapalli R, Barjaktarovic Z, Ueffing M, Conrad M, Neff F, Calzada-Wack J, Aubele M, Buske C, Atkinson MJ, Hauck SM, Tapio S. Label-free protein profiling of formalin fixed paraffin-embedded (FFPE) heart tissue reveals immediate mitochondrial impairment after ionising radiation. J Proteomics. 2012 Apr 18;75(8):2384-95.
2011
Mohr F, Döhner K, Buske C, et al. TET genes: New players in DNA demethylation and important determinants for stemness. Exp Hematol 2011; 39: 272-281.
Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Medicine 2011; 17: 1086-1093.
Kuchenbauer F, Mah SM, Heuser M, et al. Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood 2011; 118(12): 3350-3358.
Rouhi A, Buske C. Stem cells and beyond: report on the 40th Annual Scientific Meeting of the International Society of Experimental Hematology. Expert Rev Hematol 2011; 4(6): 591-592.
Deshpande AJ, Rouhi A, Lin Y, et al. The clathrin binding domain of CALM and OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia 2011; 25(11): 1718-1727.
Azimzadeh O, Scherthan H, Sarioglu H, Barjaktarovic Z, Conrad M, Vogt A, Calzada-Wack J, Neff F, Aubele M, Buske C, Atkinson MJ, Tapio S. Rapid proteomic remodeling of cardiac tissue caused by total body ionizing radiation. J Proteomics 2011 11: 3299-3311.
Herold T, Jurinovic V, Mulaw M, et al. Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected experssion pattern of the RHO GTPase activator ARHGAP20. Genes Chromosomes Center 2011; 50: 546-558.
Herold T, Jurinovic V, Metzeler KH, et al. An 8 gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia 2011; 25: 1639-1645.
2010
Rawat VP, Arseni N, Ahmed F, et al. The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2010; 107(39): 16946-19851.
Buske C. Hematologic malignancies-sixth European congress. 26-28 February 2010, Cannes, France. Drugs 2010;13:300-303.
Buske C. Indolent lymphoma in the elderly. Proceedings of the first international conference on Haematological Malignancies in the Elderley. Lissabon, Portugal, 2010; 5: 67-68.
Mah SM, Buske C. Humphries RK, Kuchenbauer F. miRNA: A passenger stranded in RNA-induced silencing complex? Crit Rev Eukariot Gene Expr 2010; 20(2): 141-148. Review.
Schöler N, Langer C, Döhner H, Buske C, Kuchenbauer F. Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Exp Hematol 2010; 38(12): 1126-30. Review.
2009
Rao AV, Valk PJ, Metzeler KH, et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol. 2009;27:5580-5586.
Deshpande A, Pastore A, Deshpande AJ, et al. 3'UTR mediated regulation of the cyclin D1 proto-oncogene. Cell Cycle. 2009;8:3584-3592.
Metzeler KH, Dufour A, Benthaus T, et al. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol. 2009;27:5031-5038.
Deshpande AJ, Ahmed F, Buske C. Identification of murine and human acute myeloid leukemia stem cells. Methods Mol Biol. 2009;568:21-35.
Heilmeier B, Spiekermann K, Bohlander S, et al. [Modern leukemia diagnosis in adults]. Dtsch Med Wochenschr. 2009;134:1222-1226.
Lin YH, Kakadia PM, Chen Y, et al. Global reduction of the epigenetic H3K79 methylation mark and increased chromosomal instability in CALM-AF10-positive leukemias. Blood. 2009;114:651-658.
Schneider F, Hoster E, Unterhalt M, et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood. 2009;113:5250-5253.
Reindl C, Quentmeier H, Petropoulos K, et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res. 2009;15:2238-2247.
Thoene S, Rawat VP, Heilmeier B, et al. The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia. Leukemia. 2009;23:649-655.
Braess J, Spiekermann K, Staib P, et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood. 2009;113:3903-3910.
Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23:153-161.
2008
Buske C, Gisselbrecht C, Gribben J, Letai T, McLaughlin P, Wilson W. Refining the treatment of follicular lymphoma. Leuk Lymphoma. 2008;49 Suppl 1:18-26.
Archangelo LF, Greif PA, Holzel M, et al. The CALM and CALM/AF10 interactor CATS is a marker for proliferation. Mol Oncol. 2008;2:356-367.
Metzeler KH, Hummel M, Bloomfield CD, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008;112:4193-4201.
Vempati S, Reindl C, Wolf U, et al. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591. Clin Cancer Res. 2008;14:4437-4445.
Petropoulos K, Arseni N, Schessl C, et al. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med. 2008;205:515-522.
Ahmed F, Arseni N, Glimm H, Hiddemann W, Buske C, Feuring-Buske M. Constitutive expression of the ATP-binding cassette transporter ABCG2 enhances the growth potential of early human hematopoietic progenitors. Stem Cells. 2008;26:810-818.
Rawat VP, Thoene S, Naidu VM, et al. Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia. Blood. 2008;111:309-319.
2007
Schmitz N, Buske C, Gisselbrecht C. Autologous stem cell transplantation in lymphoma. Semin Hematol. 2007;44:234-245.
Deshpande AJ, Buske C. Knocking the Wnt out of the sails of leukemia stem cell development. Cell Stem Cell. 2007;1:597-598.
Buske C, Hiddemann W. [The older patient with malignant diseases]. Internist (Berl). 2007;48:1206,1208-1210.
Metzeler KH, Braess J, Spiekermann K, et al. [Fortuitous finding: thrombocytopenia and thrombocytosis]. MMW Fortschr Med. 2007;149:34-35, 37.
Schneider F, Bohlander SK, Schneider S, et al. AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia. Leukemia. 2007;21:2199-2201.
Kohl TM, Hellinger C, Ahmed F, et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia. 2007;21:1763-1772.
Fritsch S, Buske C, Wormann B, Wedding U, Hiddemann W, Spiekermann K. [Therapy of acute myeloid leukemia (AML) for medically non-fit patients]. Med Klin (Munich). 2007;102:324-329.
Heilmeier B, Buske C, Spiekermann K, et al. [Diagnostics, classification and prognostic criteria of acute myeloid leukemia]. Med Klin (Munich). 2007;102:296-308.
Christ O, Feuring-Buske M, Hiddemann W, Buske C. [Pathobiology of acute myeloid leukemia]. Med Klin (Munich). 2007;102:290-295.
Buske C, Hiddemann W. [Malignant lymphoma--there are still many open questions]. Internist (Berl). 2007;48:349-350.
Deshpande AJ, Buske C. Lymphoid progenitors as candidate cancer stem cells in AML: new perspectives. Cell Cycle. 2007;6:543-545.
Buske C, Unterhalt M, Hiddeman W. [Therapy of follicular lymphoma]. Internist (Berl). 2007;48:372-381.
Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Unterhalt M. Current management of follicular lymphomas. Br J Haematol. 2007;136:191-202.
2006
Deshpande AJ, Cusan M, Rawat VP, et al. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell. 2006;10:363-374.
Fritsch S, Metzeler K, Hiddemann W, Buske C. [Diagnostics and therapy of acute myeloid leukemia]. Dtsch Med Wochenschr. 2006;131:2401-2406.
Kuchenbauer F, Schnittger S, Look T, et al. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol. 2006;134:616-619.
Weigert O, Dreyling M, Unterhalt M, Hiddemann W, Buske C. Investigational strategies in autologous stem cell transplantation for follicular lymphoma. Curr Oncol Rep. 2006;8:368-375.
Metzeler K, Fritsch S, Buske C, Hiddemann W. [Acute myeloid leukemia -- on the way towards pathogenesis-oriented treatment]. Dtsch Med Wochenschr. 2006;131:1466-1468.
Hiddemann W, Spiekermann K, Braess J, Feuring-Buske M, Buske C, Buchner T. [Risk-adapted therapy of acute myeloid leukemia]. Internist (Berl). 2006;47 Suppl 1:S33-39.
Buske C, Hiddemann W. Rituximab maintenance therapy in indolent NHL: a clinical review. Leuk Res. 2006;30 Suppl 1:S11-15.
Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504-1508.
Buske C, Glimm H, Feuring-Buske M. [Stem cell therapy. Biology of hematopoietic stem cells]. Internist (Berl). 2006;47:459-460, 462-454.
Buske C, Weigert O, Dreyling M, Unterhalt M, Hiddemann W. Current status and perspective of antibody therapy in follicular lymphoma. Haematologica. 2006;91:104-112.
Feuring-Buske M, Hartmann EM, Ott G, Reuter H, Buske C, Rosenwald A. [DNA-chips in the diagnosis of hematological malignancies]. Internist (Berl). 2006;47:39-46.
2005
Kuchenbauer F, Feuring-Buske M, Buske C. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia. Cell Cycle. 2005;4:1716-1718.
Arseni N, Ahmed F, Hiddemann W, Buske C, Feuring-Buske M. Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells. Haematologica. 2005;90:1577-1578.
Hiddemann W, Spiekermann K, Buske C, et al. Towards a pathogenesis-oriented therapy of acute myeloid leukemia. Crit Rev Oncol Hematol. 2005;56:235-245.
Dreyling M, Buske C, Hiddemann W. [Up-to-date treatment of follicular lymphomas]. Dtsch Med Wochenschr. 2005;130:2149-2154.
Hiddemann W, Buske C, Dreyling M, et al. Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol. 2005;23:6394-6399.
Schessl C, Rawat VP, Cusan M, et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest. 2005;115:2159-2168.
Dreyling M, Buske C, Hiddemann W. Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma. Ann Oncol. 2005;16 Suppl 2:ii99-104.
Buske C, Dreyling M, Unterhalt M, Hiddemann W. Transplantation strategies for patients with follicular lymphoma. Curr Opin Hematol. 2005;12:266-272.
Buske C, Dreyling M, Unterhalt M, Hiddemann W. [Monoclonal antibody therapy for malignant lymphoma]. Med Klin (Munich). 2005;100:14-24.
2004- 2000
Buske C, Dreyling M, Unterhalt M, Hiddemann W. [Monoclonal antibody treatment of malignant lymphoma]. Internist (Berl). 2004;45:1370-1377.
Buske C, Dreyling H, Unterhalt M, Hiddemann W. Novel treatment strategies in follicular lymphoma. Ann Hematol. 2004;83 Suppl 1:S72.
Rawat VP, Cusan M, Deshpande A, et al. Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. Proc Natl Acad Sci U S A. 2004;101:817-822.
Pineault N, Buske C, Feuring-Buske M, et al. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood. 2003;101:4529-4538.
Spiekermann K, Dirschinger RJ, Schwab R, et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood. 2003;101:1494-1504.
Feuring-Buske M, Hiddemann W, Buske C. [Pathogenesis and biology of leukemias]. Internist (Berl). 2002;43:1179-1189.
Buske C, Hiddemann W. [Acute and chronic leukemias. Current aspects of pathogenesis, diagnosis and therapy]. Internist (Berl). 2002;43:1177-1178.
Buske C, Feuring-Buske M, Abramovich C, et al. Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells. Blood. 2002;100:862-868.
Blaschke S, Hannig H, Buske C, Kaup FJ, Hunsmann G, Bodemer W. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques. J Med Virol. 2001;65:114-120.
Buske C, Feuring-Buske M, Antonchuk J, et al. Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo. Blood. 2001;97:2286-2292.
Buske C, Humphries RK. Homeobox genes in leukemogenesis. Int J Hematol. 2000;71:301-308.